Motivation: Rigorous monitoring is clearly needed to fully evaluate efficacy of new anti-amyloid therapeutics against AD.
Goal(s): To evaluate the value of protein-based APT MRI in monitoring AD immunotherapy efficacy and characterizing adverse events.
Approach: Both animal AD models and human subjects were studied, and a novel APT acquisition and quantitative analysis approach (EMR-APT) was used.
Results: The average APT signals were significantly higher in AD mice than in wild-type controls. Similarly, the MCI patients demonstrated significantly higher APT signals, compared to the normal controls.
Impact: A unique and innovative biomarker-stratified approach developed in this work will aid in assessing treatment efficacy accurately and identifying adverse events early.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords